What Aggra Treats: Main Uses and Benefits

Aggra (sildenafil) is commonly used to help with two distinct, relevant therapeutic domains, supports the patient during difficult episodes and contributes to improved comfort during periods of heightened symptoms.

Therapeutic Domains

The medication is applied across domains where additional symptomatic support is needed, including Erectile Dysfunction (ED) and Pulmonary Arterial Hypertension (PAH). It helps address symptom clusters that may become intense or disruptive, such as symptoms related to physical discomfort and symptoms that interfere with daily functioning. This therapeutic role provides supportive relief when symptoms interfere with routine activities and may help patients cope more steadily with symptom fluctuations. It is considered relevant in contexts marked by increased discomfort or tension, assisting patients with managing pronounced symptoms associated with these conditions.

Quick Fact: Relief for Symptoms that Interfere with Daily Functioning and symptoms related to heightened physiological activity.

Regulatory References

1. NIH MedlinePlus overview of Sildenafil

Official Eligibility Status for Aggra (Sildenafil)

Aggra is officially indicated for use only in Adult Men aged 18 years and over for the treatment of erectile dysfunction. Its eligibility profile is strictly defined by regulatory agencies and includes absolute prohibitions, use-not-established groups, and restrictions based on health status.

Connection to the overall eligibility profile

Official regulatory documents mandate that use is strictly Contraindicated in any patient taking nitrates or GC stimulators due to life-threatening safety risks. The profile further limits eligibility based on specific pre-existing cardiovascular status and organ health. Certain patient populations, including those with severe kidney or liver impairment, require cautious use as detailed in the official prescribing information.

Interactions with other medicines and products

Aggra (sildenafil) has documented interaction patterns primarily involving pharmacodynamic effects on blood pressure and pharmacokinetic effects on drug clearance, as described in official regulatory labeling.

Contraindicated Combinations

Regulatory documents strictly state that co-administration is contraindicated with organic nitrates (including all forms of nitroglycerin) and with Guanylate Cyclase (GC) Stimulators (e.g., Riociguat). This prohibition is due to the potential for sildenafil to dangerously potentiate the hypotensive (blood pressure lowering) effects of these agents.

Pharmacokinetic Interactions

Sildenafil is mainly cleared via the Cytochrome P450 3A4 (CYP3A4) enzyme. Co-administration with potent CYP3A4 inhibitors (e.g., Ritonavir, Ketoconazole) officially increases sildenafil's systemic exposure (plasma concentration). Conversely, CYP3A4 inducers (e.g., Rifampin) can decrease exposure. Due to this risk, the maximum dose and frequency must be reduced when co-administered with certain strong inhibitors, such as Ritonavir, to control systemic levels as specified by regulatory agencies.

Other Documented Interactions

Co-administration with alpha-blockers (e.g., Doxazosin) may lead to additive blood pressure lowering effects. To manage this potential, some regulatory texts recommend a specific time separation between the doses. A high-fat meal is documented to delay the rate of absorption of sildenafil, thus increasing the time until maximum concentration is achieved. Interactions resulting in increased exposure are more pronounced in populations with severe hepatic or renal impairment due to their reduced clearance mechanisms.

How Aggra Works: Mechanism of Action

The mechanism of Aggra, based on Sildenafil, involves the selective inhibition of a key enzyme, which modulates the local signaling pathway that regulates vascular smooth muscle tone.

Selective Inhibition of the PDE5 Enzyme

Sildenafil's primary action occurs at the molecular level, targeting the Phosphodiesterase type 5 (PDE5) enzyme and the key messenger molecule, cGMP. Sildenafil functions as a selective competitive inhibitor of PDE5, an enzyme that hydrolyzes and terminates the cGMP signal. Blocking this termination prevents cGMP breakdown, allowing the molecule to accumulate within vascular smooth muscle cells.

Conditional Modulation of the Vasodilatory Signal

This modulation of the Nitric Oxide (NO) / cGMP signaling cascade produces the final physiological change of vasodilation. Sildenafil functions by amplifying an existing signal, meaning the mechanism is strictly conditional upon the physiological release of NO. This release is required to generate the cGMP substrate, without which the drug’s mechanism cannot be engaged. The resulting cGMP accumulation promotes the relaxation of specific vascular smooth muscle, which physiologically facilitates localized vasodilation.

Word Count: 147

Administration Principles

Aggra (sildenafil) administration adheres to two distinct protocols based on the condition being addressed, utilizing oral (tablet and suspension) and intravenous (IV) routes. Its administration is defined by specific frequency and dose limits.

Usage for Erectile Dysfunction (ED)

The oral tablet is used on an as-needed basis, with administration limited to a maximum frequency of once per day. The initial dose is 50 mg, which can be adjusted within a range of 25 mg to 100 mg. The medicine should be taken approximately one hour before activity. While it can be taken with or without food, consumption with a high-fat meal may lead to a delay in the onset of activity. For specific populations, including older adults (65 years and older) and individuals with severe kidney or liver impairment, a lower 25 mg starting dose is considered due to altered drug clearance.

Usage for Pulmonary Arterial Hypertension (PAH)

For PAH, the medicine is used as a continuous, scheduled therapy. The oral dose is typically 20 mg, taken three times a day (TID), with doses spaced by four to six hours. The IV injection (10 mg) is restricted for use only when a patient is temporarily unable to take the oral dose. If a dose is missed, patients should resume the schedule at the next regularly scheduled time. The oral suspension requires reconstitution with water and vigorous shaking before being measured and administered.

Research evidence / Overview of studies for Aggra (Sildenafil)

Evidence for use in Erectile Dysfunction (ED)

The research base for the evaluation of Aggra in erectile dysfunction primarily consists of numerous Randomized Controlled Trials (RCTs). These short-term studies, a type of study often used to evaluate investigational medicines, were typically double-blind, comparing the medicine against an inactive placebo. The studies included adult men with varying degrees of ED caused by different factors. Researchers primarily monitored changes in function by collecting patient-reported outcomes, tracking measurements of erectile function scores and successful sexual attempts. Findings describe patterns observed in the studies related to differences in patient-reported function scores between groups over the trial period.

Evidence for use in Pulmonary Arterial Hypertension (PAH)

The evidence supporting the evaluation for pulmonary arterial hypertension (PAH) is derived from randomized, placebo-controlled trials conducted over intermediate time intervals, such as 12 to 16 weeks. These studies explored how the medicine was associated with outcomes reflecting daily functioning or activity level in adult patients, with specific trials also conducted for pediatric patients. Research examined changes in exercise capacity, most commonly measured by the 6-minute walk distance (6MWD). Studies also monitored outcomes like the time until a clinical worsening event and changes in WHO Functional Class.

Limitations and Uncertainties

Evidence quality varies across studies, and comparative evidence of the medicine against all other available treatments in its class remains limited. Limited information is available for long-term outcomes beyond the observation windows of the extension trials. In special populations, higher doses were observed to be associated with an increased risk of mortality in the specific pediatric PAH studies. In general, research provides context but not individual predictions; results apply only to the populations studied, and findings describe group patterns.

Key Studies & References

1. SILDENAFIL CITRATE- sildenafil tablet, film coated (US FDA DailyMed Label)

How to Store and Dispose of Aggra (Sildenafil)

The storage and disposal of Aggra must adhere strictly to regulatory conditions to ensure stability and safety, as outlined in official labeling.

Storage Requirements

Aggra tablets must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The product must be kept in its original, tightly closed container and protected from excess heat, moisture, and light. It is mandatory to keep this medication out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired sildenafil should be disposed of promptly. The regulatory preferred method is through an official drug take-back program. If a take-back option is unavailable, the tablets should be mixed with an unappealing substance, placed in a sealed bag, and discarded in the household trash. Sildenafil is not on the list of medicines recommended for flushing.